Global Alpha Emitters Market - Growth, Trends and Forecasts 2017 - 2022

  • ID: 4387690
  • Report
  • Region: Global
  • 205 pages
  • Mordor Intelligence
1 of 4
The global market for alpha emitters has been estimated at $XX million for the year 2014 and is projected to reach $XX million by 2020 at a CAGR of XX% during the forecast period 2014 to 2021. Alpha emitters are radioactive substances that decay after emitting alpha particles. Alpha emitter radionuclide is considered to be a new approach to treat many cancer types. Alpha-particles offer specific tumor cell killing action causing less damage to surrounding normal tissues than beta-emitters and this potential has caught market attention.

The targeted delivery of alpha emitter labeled radionuclides are being used to treat glioblastoma, ovarian cancer, lymphoma, melanoma, pancreatic cancer, gastric cancer, breast cancer, bone Metastasis and bladder cancer. Alpha emitter therapy holds a great promise when compared to chemotherapy as targeted alpha therapy allows easy discrimination between the healthy cells and cancer cells. The end-users of this market are usually Hospital, Imaging centers and research laboratories.

Increasing incidences of cancer, the therapeutic efficacy of alpha-emitter radionuclides and increased awareness about the potential benefits of targeted alpha therapy are the factors driving this market. Whereas, the lack of widespread availability of alpha-emitters, concerns regarding the potential toxicity of these agents, shorter life of radiopharmaceuticals, need for high capital investment, stringent regulatory framework and reimbursement issues are the major factors impacting market growth.

Alpha Emitters market can be segmented on basis of Radionuclide Types which include Terbium (Tb-149), Astatine (At-211), Bismuth (Bi-212), Bismuth (Bi-213), Actinium (Ac-225), Radium (Ra-223), Lead (Pb-212) and others.

Based on geography, the market is segmented into North America, Europe, Asia-Pacific and Rest of World. Developing countries like India hold strong market potential for alpha emitter therapy. Europe has large number of alpha emitter therapeutic procedures than North America, thereby, European market dominates the American market.

Many players in this market are trying to expand their product portfolio in order to top the global market. While few companies are entering into the market by acquisitions, top companies are expanding their growth in this market by acquiring other companies. Few companies adopted product innovation and new product launches as its key business strategy to ensure its dominance in this market. Major players in the market are Mallinckrodt, Lantheus medical imaging, IBA Group, Traid Isotope, Siemens Healthcare and NTP Radioisotopes.

Key Deliverables:

Market analysis for the Global Alpha Emitters Market, with region specific assessments and competition analysis on global and regional scales
Market definition along with the identification of key drivers and restraints
Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale
Extensively researched competitive landscape section with profiles of major companies along with their market shares
Identification and analysis of the macro and micro factors that affect the Global Alpha Emitters Market on both global and regional scales
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information
A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market
Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
Note: Product cover images may vary from those shown
2 of 4
1. Executive Summary
2. Introduction
2.1 Report Description
2.2 Research Methodology
3. Market Overview
3.1 Market Segmentation
3.2 Market Drivers
3.2.1 Increasing incidences of cardiac & cancer ailments
3.2.2 Increased awareness about the potential benefits of targeted alpha therapy
3.2.3 Ready availability of radiopharmaceuticals
3.3 Market Restraints
3.3.1 Shorter half-life of radiopharmaceuticals
3.3.2 Need for high capital investment
3.3.3 Stringent regulatory framework
3.3.4 Reimbursement issues
3.4 Market Opportunities
3.5 Market Threats
4. Porters Five Force Analysis
4.1 Bargaining Power of Suppliers
4.2 Bargaining Power of Buyers
4.3 Internal Rivalry
4.4 Threat of Substitution
4.5 Threat of New Entrants
5. Global Alpha Emitters Market Segmentation
5.1 Segmentation by Type of Radionuclide
5.1.1 Terbium (Tb-149)
5.1.2 Astatine (At-211)
5.1.3 Bismuth (Bi-212)
5.1.4 Actinium (Ac-225)
5.1.5 Radium (Ra-223)
5.1.6 Lead (Pb-212)
5.1.7 Bismuth (Bi -213)
5.1.8 Others
5.2 Segmentation by Medical Application
5.2.1 Glioma
5.2.2 Melanoma
5.2.3 Pancreatic Cancer
5.2.4 Ovarian Cancer
5.2.5 Thyroid
5.2.6 Bone Metastasis
5.2.7 Lymphoma
5.2.8 Endocrine Tumors
5.2.9 Others
5.3 Segmentation by Geography
5.3.1 North America US Canada
5.3.2 Europe UK Germany France Sweden Finland Norway Netherlands Spain Italy Others
5.3.3 Asia Pacific China Japan South Korea India Australia Others
5.3.4 Middle East & Africa Saudi Arabia UAE South Africa Others
5.3.5 Latin America Brazil Argentina Mexico Others
6. Competitive Landscape
6.1 Mergers & Acquisitions
6.2 Collaborations, Agreements, & Partnerships
6.3 New Product Launches
7. Company Profiles
7.1 IBA Group
7.2 Lantheus Medical Imaging
7.3 Triad Isotopes
7.4 Siemens Healthcare (PETNET Solutions)
7.5 NTP Radioisotopes
Note: Product cover images may vary from those shown
3 of 4


4 of 4
Note: Product cover images may vary from those shown